Hijacked in cancer: The KMT2 (MLL) family of methyltransferases

Nature Reviews Cancer

Volumn 15, Issue 6, 2015, Pages 334-346

  Rao, Rajesh C ^a   Dou, Yali ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE LYSINE METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE 2A; HISTONE LYSINE METHYLTRANSFERASE 2B; HISTONE LYSINE METHYLTRANSFERASE 2C; HISTONE LYSINE METHYLTRANSFERASE 2D; HISTONE LYSINE METHYLTRANSFERASE 2F; HISTONE LYSINE METHYLTRANSFERASE 2G; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG; MLL PROTEIN, HUMAN; PROTEIN SUBUNIT;

CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL MATURATION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DNA METHYLATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; EXOME; GERMLINE MUTATION; HUMAN; MISSENSE MUTATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TARGETING; REVIEW; SOMATIC MUTATION; SUMOYLATION; TRANSCRIPTION REGULATION; CHEMISTRY; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PROTEIN SUBUNIT;

HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASMS; PROTEIN SUBUNITS;

EID: 84929925487     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3929     Document Type: Review

References (193)

1. Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41-45 (2000).
2. Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074-1080 (2001).
3. Shilatifard, A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 75, 243-269 (2006).
4. Schuettengruber, B. , Martinez, A. M. , Iovino, N. & Cavalli, G. Trithorax group proteins: switching genes on and keeping them active. Nature Rev. Mol. Cell Biol. 12, 799-814 (2011).
5. Feinberg, A. P. , Ohlsson, R. & Henikoff, S. The epigenetic progenitor origin of human cancer. Nature Rev. Genet. 7, 21-33 (2006).
6. Rodriguez-Paredes, M. & Esteller, M. Cancer epigenetics reaches mainstream oncology. Nature Med. 17, 330-339 (2011).
7. Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nature Rev. Cancer 7, 823-833 (2007).
8. Liedtke, M. & Cleary, M. L. Therapeutic targeting of MLL. Blood 113, 6061-6068 (2009).
9. McCabe, N. R. et al. Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 translocations. Proc. Natl Acad. Sci. USA 89, 11794-11798 (1992).
10. Tkachuk, D. C. , Kohler, S. & Cleary, M. L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71, 691-700 (1992).
11. Cimino, G. et al. Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23),t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. Cancer Res. 51, 6712-6714 (1991).
12. Djabali, M. et al. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukemias. Nature Genet. 2, 113-118 (1992).
13. Milne, T. A. et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 10, 1107-1117 (2002).
14. Nakamura, T. et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol. Cell 10, 1119-1128 (2002).
15. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
16. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
17. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
18. FitzGerald, K. T. & Diaz, M. O. MLL2: a new mammalian member of the trx/MLL family of genes. Genomics 59, 187-192 (1999).
19. Pijnappel, W. W. et al. The S. cerevisiae SET3 complex includes two histone deacetylases, Hos2 and Hst1, and is a meiotic-specific repressor of the sporulation gene program. Genes Dev. 15, 2991-3004 (2001).
20. Goo, Y. H. et al. Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins. Mol. Cell. Biol. 23, 140-149 (2003).
21. Hughes, C. M. et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 13, 587-597 (2004).
22. Cho, Y. W. et al. PTIP associates with MLL3-and MLL4-containing histone H3 lysine 4 methyltransferase complex. J. Biol. Chem. 282, 20395-20406 (2007).
23. Lee, J. H. & Skalnik, D. G. CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex. J. Biol. Chem. 280, 41725-41731(2005).
24. Lee, J. H. , Tate, C. M. , You, J. S. & Skalnik, D. G. Identification and characterization of the human Set1B histone H3-Lys4 methyltransferase complex. J. Biol. Chem. 282, 13419-13428 (2007).
25. Dou, Y. et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121, 873-885 (2005).
26. Dou, Y. et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nature Struct. Mol. Biol. 13, 713-719 (2006).
27. Patel, A. , Dharmarajan, V. , Vought, V. E. & Cosgrove, M. S. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. J. Biol. Chem. 284, 24242-24256 (2009).
28. Takahashi, Y. H. et al. Structural analysis of the core COMPASS family of histone H3K4 methylases from yeast to human. Proc. Natl Acad. Sci. USA 108, 20526-20531 (2011).
29. Patel, A. , Dharmarajan, V. & Cosgrove, M. S. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide. J. Biol. Chem. 283, 32158-32161 (2008).
30. Chen, Y. , Cao, F. , Wan, B. , Dou, Y. & Lei, M. Structure of the SPRY domain of human Ash2L and its interactions with RbBP5 and DPY30. Cell Res. 22, 598-602 (2012).
31. Chen, Y. et al. Crystal structure of the N-terminal region of human Ash2L shows a winged-helix motif involved in DNA binding. EMBO Rep. 12, 797-803 (2011).
32. Schuetz, A. et al. Structural basis for molecular recognition and presentation of histone H3 by WDR5. EMBO J. 25, 4245-4252 (2006).
33. Couture, J. F. , Collazo, E. & Trievel, R. C. Molecular recognition of histone H3 by the WD40 protein WDR5. Nature Struct. Mol. Biol. 13, 698-703 (2006).
34. Sarvan, S. et al. Crystal structure of the trithorax group protein ASH2L reveals a forkhead-like DNA binding domain. Nature Struct. Mol. Biol. 18, 857-859 (2011).
35. Ruthenburg, A. J. et al. Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex. Nature Struct. Mol. Biol. 13, 704-712 (2006).
36. Southall, S. M. , Wong, P. S. , Odho, Z. , Roe, S. M. & Wilson, J. R. Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol. Cell 33, 181-191 (2009).
37. Steward, M. M. et al. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nature Struct. Mol. Biol. 13, 852-854 (2006).
38. Cao, F. et al. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain. PLoS ONE 5, e14102 (2010).
39. Patel, A. et al. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation. J. Biol. Chem. 289, 868-884 (2014).
40. Song, J. J. & Kingston, R. E. WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket. J. Biol. Chem. 283, 35258-35264 (2008).
41. Avdic, V. et al. Structural and biochemical insights into MLL1 core complex assembly. Structure 19, 101-108 (2011).
42. Patel, A. , Vought, V. E. , Dharmarajan, V. & Cosgrove, M. S. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex. J. Biol. Chem. 283, 32162-32175 (2008).
43. Dharmarajan, V. , Lee, J. H. , Patel, A. , Skalnik, D. G. & Cosgrove, M. S. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases. J. Biol. Chem. 287, 27275-27289 (2012).
44. Karatas, H. , Townsend, E. C. , Bernard, D. , Dou, Y. & Wang, S. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. J. Med. Chem. 53, 5179-5185 (2010).
45. Cao, F. et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 53, 247-261 (2014).
46. Karatas, H. et al. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J. Am. Chem. Soc. 135, 669-682 (2013).
47. Senisterra, G. et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem. J. 449, 151-159 (2013).
48. Hsieh, J. J. , Cheng, E. H. & Korsmeyer, S. J. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 115, 293-303 (2003).
49. Yokoyama, A. , Kitabayashi, I. , Ayton, P. M. , Cleary, M. L. & Ohki, M. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood 100, 3710-3718 (2002).
50. Yokoyama, A. et al. MLL becomes functional through intra-molecular interaction not by proteolytic processing. PLoS ONE 8, e73649 (2013).
51. Wu, L. et al. ASH2L regulates ubiquitylation signaling to MLL: trans-regulation of H3 K4 methylation in higher eukaryotes. Mol. Cell 49, 1108-1120 (2013).
52. Lee, J. E. et al. H3K4 mono-and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. eLife 2, e01503 (2013).
53. Dhar, S. S. et al. Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4. Genes Dev. 26, 2749-2762 (2012).
54. Tang, Z. et al. SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53. Cell 154, 297-310 (2013).
55. Nayak, A. , Viale-Bouroncle, S. , Morsczeck, C. & Muller, S. The SUMO-specific isopeptidase SENP3 regulates MLL1/MLL2 methyltransferase complexes and controls osteogenic differentiation. Mol. Cell 55, 47-58 (2014).
56. van Nuland, R. et al. Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. Mol. Cell. Biol. 33, 2067-2077 (2013).
57. Yokoyama, A. & Cleary, M. L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14, 36-46 (2008).
58. Murai, M. J. et al. The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV. Blood 124, 3730-3737 (2014).
59. Mo, R. , Rao, S. M. & Zhu, Y. J. Identification of the MLL2 complex as a coactivator for estrogen receptor ?. J. Biol. Chem. 281, 15714-15720 (2006).
60. Patel, S. R. , Kim, D. , Levitan, I. & Dressler, G. R. The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev. Cell 13, 580-592 (2007).
61. Tyagi, S. , Chabes, A. L. , Wysocka, J. & Herr, W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol. Cell 27, 107-119 (2007).
62. Takeda, S. et al. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev. 20, 2397-2409 (2006).
63. Lee, J. et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc. Natl Acad. Sci. USA 106, 8513-8518 (2009).
64. Aziz, A. , Liu, Q. C. & Dilworth, F. J. Regulating a master regulator: Establishing tissue-specific gene expression in skeletal muscle. Epigenetics 5, 691-695 (2010).
65. Kawabe, Y. , Wang, Y. X. , McKinnell, I. W. , Bedford, M. T. & Rudnicki, M. A. Carm1 regulates Pax7 transcriptional activity through MLL1/2 recruitment during asymmetric satellite stem cell divisions. Cell Stem Cell 11, 333-345 (2012).
66. Demers, C. et al. Activator-mediated recruitment of the MLL2 methyltransferase complex to the globin locus. Mol. Cell 27, 573-584 (2007).
67. Tan, C. C. et al. Transcription factor Ap2 associates with Ash2l and ALR, a trithorax family histone methyltransferase, to activate Hoxc8 transcription. Proc. Natl Acad. Sci. USA 105, 7472-7477 (2008).
68. Fossati, A. , Dolfini, D. , Donati, G. & Mantovani, R. NF-Y recruits Ash2L to impart H3K4 trimethylation on CCAAT promoters. PLoS ONE 6, e17220 (2011).
69. Deng, C. et al. USF1 and hSET1A mediated epigenetic modifications regulate lineage differentiation and HoxB4 transcription. PLoS Genet. 9, e1003524 (2013).
70. Ang, Y. S. et al. Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell 145, 183-197 (2011).
71. Kaikkonen, M. U. et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 51, 310-325 (2013).
72. Guenther, M. G. et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc. Natl Acad. Sci. USA 102, 8603-8608 (2005).
73. Allen, M. D. et al. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J. 25, 4503-4512 (2006).
74. Saxonov, S. , Berg, P. & Brutlag, D. L. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl Acad. Sci. USA 103, 1412-1417 (2006).
75. Wang, Z. et al. Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 141, 1183-1194 (2010).
76. Plevin, M. J. , Mills, M. M. & Ikura, M. The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. Trends Biochem. Sci. 30, 66-69 (2005).
77. Bustin, M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol. 19, 5237-5246 (1999).
78. Yang, Y. W. et al. Essential role of lncRNA binding for WDR5 maintenance of active chromatin and embryonic stem cell pluripotency. eLife 3, e02046 (2014).
79. Wang, K. C. et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472, 120-124 (2011).
80. Bach, C. , Mueller, D. , Buhl, S. , Garcia-Cuellar, M. P. & Slany, R. K. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene 28, 815-823 (2009).
81. Wang, P. et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. 29, 6074-6085 (2009).
82. Austenaa, L. et al. The histone methyltransferase Wbp7 controls macrophage function through GPI glycolipid anchor synthesis. Immunity 36, 572-585 (2012).
83. Guo, C. et al. Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc. Natl Acad. Sci. USA 109, 17603-17608 (2012).
84. Jiang, H. et al. Regulation of transcription by the MLL2 complex and MLL complex-associated AKAP95. Nature Struct. Mol. Biol. 20, 1156-1163 (2013).
85. Ruthenburg, A. J. , Allis, C. D. & Wysocka, J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol. Cell 25, 15-30 (2007).
86. Vermeulen, M. & Timmers, H. T. Grasping trimethylation of histone H3 at lysine 4. Epigenomics 2, 395-406 (2010).
87. Ruthenburg, A. J. , Li, H. , Patel, D. J. & Allis, C. D. Multivalent engagement of chromatin modifications by linked binding modules. Nature Rev. Mol. Cell Biol. 8, 983-994 (2007).
88. Taverna, S. D. , Li, H. , Ruthenburg, A. J. , Allis, C. D. & Patel, D. J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nature Struct. Mol. Biol. 14, 1025-1040 (2007).
89. Leung, A. et al. Histone H2B ubiquitylation and H3 lysine 4 methylation prevent ectopic silencing of euchromatic loci important for the cellular response to heat. Mol. Biol. Cell 22, 2741-2753 (2011).
90. Auriemma, L. B. , Shah, S. , Linden, L. M. & Henriksen, M. A. Knockdown of menin affects pre-mRNA processing and promoter fidelity at the interferon inducible IRF1 gene. Epigenetics Chromatin 5, 2 (2012).
91. van Dijk, E. L. et al. XUTs are a class of Xrn1-sensitive antisense regulatory non-coding RNA in yeast. Nature 475, 114-117 (2011).
92. Calo, E. & Wysocka, J. Modification of enhancer chromatin: what, how, and why? Mol. Cell 49, 825-837 (2013).
93. Buecker, C. & Wysocka, J. Enhancers as information integration hubs in development: lessons from genomics. Trends Genet. 28, 276-284 (2012).
94. Lara-Astiaso, D. et al. Immunogenetics. Chromatin state dynamics during blood formation. Science 345, 943-949 (2014).
95. Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-112 (2009).
96. Akhtar-Zaidi, B. et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 336, 736-739 (2012).
97. Herz, H. M. , Hu, D. & Shilatifard, A. Enhancer malfunction in cancer. Mol. Cell 53, 859-866 (2014).
98. Blobel, G. A. et al. A reconfigured pattern of MLL occupancy within mitotic chromatin promotes rapid transcriptional reactivation following mitotic exit. Mol. Cell 36, 970-983 (2009).
99. Ooi, S. K. et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448, 714-717 (2007).
100. Zhang, Y. et al. Chromatin methylation activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone H3 tail. Nucleic Acids Res. 38, 4246-4253 (2010).
101. Thomson, J. P. et al. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature 464, 1082-1086 (2010).
102. Deaton, A. M. & Bird, A. CpG islands and the regulation of transcription. Genes Dev. 25, 1010-1022 (2011).
103. Erfurth, F. E. et al. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc. Natl Acad. Sci. USA 105, 7517-7522 (2008).
104. Risner, L. E. et al. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. J. Biol. Chem. 288, 29901-29910 (2013).
105. Cierpicki, T. et al. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nature Struct. Mol. Biol. 17, 62-68 (2010).
106. Clouaire, T. et al. Cfp1 integrates both CpG content and gene activity for accurate H3K4me3 deposition in embryonic stem cells. Genes Dev. 26, 1714-1728 (2012).
107. Deplus, R. et al. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J. 32, 645-655 (2013).
108. Petruk, S. et al. TrxG and PcG proteins but not methylated histones remain associated with DNA through replication. Cell 150, 922-933 (2012).
109. Wang, J. , Muntean, A. G. , Wu, L. & Hess, J. L. A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity. J. Biol. Chem. 287, 43410-43416 (2012).
110. Wang, J. , Muntean, A. G. & Hess, J. L. ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood 119, 1151-1161 (2012).
111. Liu, H. , Cheng, E. H. & Hsieh, J. J. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev. 21, 2385-2398 (2007).
112. Liu, H. et al. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467, 343-346 (2010).
113. Soares, L. M. , Radman-Livaja, M. , Lin, S. G. , Rando, O. J. & Buratowski, S. Feedback control of Set1 protein levels is important for proper H3K4 methylation patterns. Cell Rep. 6, 961-972 (2014).
114. Ayton, P. M. & Cleary, M. L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20, 5695-5707 (2001).
115. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
116. Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genet. 43, 875-878 (2011).
117. Kandoth, C. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
118. Jones, W. D. et al. De novo mutations in MLL cause Wiedemann-Steiner syndrome. Am. J. Hum. Genet. 91, 358-364 (2012).
119. Ansari, K. I. , Kasiri, S. & Mandal, S. S. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo. Oncogene 32, 3359-3370 (2013).
120. Takeda, S. et al. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J. Clin. Invest. 123, 3154-3165 (2013).
121. Thiel, A. T. et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17, 148-159 (2010).
122. Sierra, J. , Yoshida, T. , Joazeiro, C. A. & Jones, K. A. The APC tumor suppressor counteracts catenin activation and H3K4 methylation at Wnt target genes. Genes Dev. 20, 586-600 (2006).
123. Milne, T. A. et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl Acad. Sci. USA 102, 749-754 (2005).
124. Xia, Z. B. et al. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc. Natl Acad. Sci. USA 102, 14028-14033 (2005).
125. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
126. Glaser, S. et al. Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development 133, 1423-1432 (2006).
127. Glaser, S. et al. The histone 3 lysine 4 methyltransferase, Mll2, is only required briefly in development and spermatogenesis. Epigenetics Chromatin 2, 5 (2009).
128. Andreu-Vieyra, C. V. et al. MLL2 is required in oocytes for bulk histone 3 lysine 4 trimethylation and transcriptional silencing. PLoS Biol. 8, e1000453 (2010).
129. Kerimoglu, C. et al. Histone-methyltransferase MLL2 (KMT2B) is required for memory formation in mice. J. Neurosci. 33, 3452-3464 (2013).
130. Lubitz, S. , Glaser, S. , Schaft, J. , Stewart, A. F. & Anastassiadis, K. Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. Mol. Biol. Cell 18, 2356-2366 (2007).
131. Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genet. 44, 1104-1110 (2012).
132. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
133. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
134. Parsons, D. W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439 (2011).
135. Kanda, H. , Nguyen, A. , Chen, L. , Okano, H. & Hariharan, I. K. The Drosophila ortholog of MLL3 and MLL4, trithorax related, functions as a negative regulator of tissue growth. Mol. Cell. Biol. 33, 1702-1710 (2013).
136. Chen, C. et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25, 652-665 (2014).
137. Santos, M. A. et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature 514, 107-111 (2014).
138. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
139. Ansari, K. I. , Hussain, I. , Kasiri, S. & Mandal, S. S. HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen via involvement of histone methylases MLL3 and MLL4. J. Mol. Endocrinol. 48, 61-75 (2012).
140. Kim, J. H. et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res. 74, 1705-1717 (2014).
141. Guo, C. et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget 4, 2144-2153 (2013).
142. Corradin, O. et al. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 24, 1-13 (2014).
143. Hippisley-Cox, J. , Vinogradova, Y. , Coupland, C. & Parker, C. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch. Gen. Psychiatry 64, 1368-1376 (2007).
144. Takata, A. et al. Loss-of-function variants in schizophrenia risk and SETD1A as a candidate susceptibility gene. Neuron 82, 773-780 (2014).
145. Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011).
146. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).
147. Deshpande, A. J. et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell 26, 896-908 (2014).
148. Lin, C. et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 37, 429-437 (2010).
149. Yokoyama, A. , Lin, M. , Naresh, A. , Kitabayashi, I. & Cleary, M. L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17, 198-212 (2010).
150. Yang, Z. et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19, 535-545 (2005).
151. Jang, M. K. et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523-534 (2005).
152. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
153. Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013).
154. Mueller, D. et al. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol. 7, e1000249 (2009).
155. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
156. Liu, H. et al. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell 25, 530-542 (2014).
157. Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207-218 (2005).
158. Grembecka, J. et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chem. Biol. 8, 277-284 (2012).
159. Scacheri, P. C. et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2, e51 (2006).
160. Mishra, B. P. et al. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep. 7, 1239-1247 (2014).
161. So, C. W. , Karsunky, H. , Wong, P. , Weissman, I. L. & Cleary, M. L. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 103, 3192-3199 (2004).
162. Kumar, A. R. et al. Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood 103, 1823-1828 (2004).
163. Ohyashiki, K. , Kocova, M. , Ryan, D. H. , Rowe, J. M. & Sandberg, A. A. Secondary acute myeloblastic leukemia with a Ph translocation in a treated Wegener's granulomatosis. Cancer Genet. Cytogenet. 19, 331-333 (1986).
164. Bledau, A. S. et al. The H3K4 methyltransferase Setd1a is first required at the epiblast stage, whereas Setd1b becomes essential after gastrulation. Development 141, 1022-1035 (2014).
165. Yu, B. D. , Hess, J. L. , Horning, S. E. , Brown, G. A. & Korsmeyer, S. J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378, 505-508 (1995).
166. Hess, J. L. , Yu, B. D. , Li, B. , Hanson, R. & Korsmeyer, S. J. Defects in yolk sac hematopoiesis in Mll-null embryos. Blood 90, 1799-1806 (1997).
167. McMahon, K. A. et al. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 1, 338-345 (2007).
168. Lee, J. et al. Targeted inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis. Proc. Natl Acad. Sci. USA 105, 19229-19234 (2008).
169. Terranova, R. , Agherbi, H. , Boned, A. , Meresse, S. & Djabali, M. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc. Natl Acad. Sci. USA 103, 6629-6634 (2006).
170. Lee, S. et al. Coactivator as a target gene specificity determinant for histone H3 lysine 4 methyltransferases. Proc. Natl Acad. Sci. USA 103, 15392-15397 (2006).
171. Goldsworthy, M. et al. Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice. PLoS ONE 8, e61870 (2013).
172. Jude, C. D. et al. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 1, 324-337 (2007).
173. Mueller, D. et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110, 4445-4454 (2007).
174. Milne, T. A. et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol. Cell 38, 853-863 (2010).
175. Muntean, A. G. et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 17, 609-621 (2010).
176. Krivtsov, A. V. et al. Global increase in H3K79 dimethylation in murine and human MLL-AF4 lymphoblastic leukemias. Blood 110, abstr. 344 (2007).
177. Jo, S. Y. , Granowicz, E. M. , Maillard, I. , Thomas, D. & Hess, J. L. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 117, 4759-4768 (2011).
178. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005).
179. Tan, J. et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 20, 563-575 (2011).
180. Bursen, A. et al. The AF4. MLL fusion protein is capable of inducing ALL in mice without requirement of MLL. AF4. Blood 115, 3570-3579 (2010).
181. Benedikt, A. et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 25, 135-144 (2011).
182. Chen, W. et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 13, 432-440 (2008).
183. Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006).
184. Corral, J. et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85, 853-861 (1996).
185. Collins, E. C. , Pannell, R. , Simpson, E. M. , Forster, A. & Rabbitts, T. H. Inter-chromosomal recombination of Mll and Af9 genes mediated by Cre-loxP in mouse development. EMBO Rep. 1, 127-132 (2000).
186. Ng, S. B. et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nature Genet. 42, 790-793 (2010).
187. Bjornsson, H. T. et al. Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome. Sci. Transl. Med. 6, 256ra135 (2014).
188. Huang, P. H. et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol. Pharmacol. 79, 197-206 (2011).
189. Berdasco, M. & Esteller, M. Genetic syndromes caused by mutations in epigenetic genes. Hum. Genet. 132, 359-383 (2013).
190. Shinsky, S. A. et al. A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes. J. Mol. Biol. 426, 2283-2299 (2014).
191. Kleefstra, T. et al. Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability. Am. J. Hum. Genet. 91, 73-82 (2012).
192. De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209-215. (2014).
193. van Os, J. & Kapur, S. Schizophrenia. Lancet 374, 635-645 (2009).